ASTRAZENECA PHARMACEUTICALS LP

H.R. 1350, Camerons Law S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023. Issues related to the Orphan Drug Tax Credit; issues related to the deduction of research and development expenditures

H.R. 5539/S. 3131 Orphan Cures Act, (amdending orphan drug exclusion in IRA) H.R. 3876 Access to Genetic Counselor Services Act of 2023 H.R. 2666 Medicaid VBPs for Patients Act Issues related to implementation of H.R.5376 - Inflation Reduction Act of 2022 (Public Law No 117-169) Orphan drug exemption of the Implementation of the Inflation Reduction Act, Pub L 117-169 CMS Comment Solicitation on Possible Mechanisms to Address Rare Diseases and Conditions Represented by Low Volumes within the MS-DRG Structure Medicaid Drug Rebate Program Proposed Rule Centers for Medicare and Medicaid Innovation (CMMI) policy issues Value-based payment arrangements Medicare patient access to rare disease therapies, Part B and Part D drugs Medicaid Drug Rebate Program proposed rule, specifically the stacking rule Issues related to low volume Diagnosis Related Groups (DRGs) and rare therapies General issues related to diagnostic reimbursement Efforts to improve coding, coverage, and access for rare disease therapies

H.R.7085 Biosecure Act H.R. 5539/S.3131 ORPHAN Cures Act, amending orphan drug exclusion in IRA Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language), Medicare Part D reform, and inflation penalties issues related to expanding orphan drug exclusion in IRA Reauthorization of newborn screening programs Reauthorization of the pediatric priority review voucher program FDA modernization policy issues Issues related to FDA proposed regulation of lab developed tests Medicare drug price negotiation Medicaid Drug Rebate Program proposed rule PBM Reform (misc. bills) Issues related to reform of pharmacy benefit managers General issues related to health equity in rare disease and clinical trials General issues related to diagnostics for patients with rare diseases General issues related to rare disease and orphan drugs Issues related to drug pricing Issues related to the price and manufacture of inhaled medicines Issues related to importation of drugs Issues related to march-in rights

Issues related to intellectual property, data exclusivity, patent eligibility & patent law reform Issues related to pharmaceutical intellectual property (IP) General patent issues

H.R. 1350, Camerons Law H.R. 5376 - Share the Savings with Seniors Act S.866/H.R.2673, American Innovation and R&D Competitiveness Act of 2023. Issues related to the Orphan Drug Tax Credit; issues related to the deduction of research and development expenditures